Steve joined Advent in 2015, and brings 20 years of executive leadership experience in both small biotech and larger pharmaceutical companies in the UK, Japan, and Scandinavia.
He has a strong track record of R&D expertise in pre-clinical drug discovery as well as business development and corporate responsibilities. Steve was most recently COO of Coco Therapeutics and prior to that, COO and VP Corporate Development at Topotarget A/S in Copenhagen.
Steve is originally a pharmacologist with a PhD from the University of Southampton.
Steve plays a key role in Advent’s diligence into pre-clinical small molecule programs, and has been an advisor to several investee companies including Artax.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.